Current Edition

aTTP

Ablynx has announced additional results from the Phase III Hercules study with caplacizumab

Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced additional results from the Phase III HERCULES study with caplacizumab, the Company’s anti-von Willebrand factor (vWF) …

Continue Reading →
chemotherapy

Roche announces Phase III study results for the treatment of people with advanced kidney cancer

Roche has announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq® …

Continue Reading →
antibiotic

Bayer/Nektar experimental inhaled antibiotic fails in Phase III

Bayer and Nektar Therapeutics’ experimental inhaled antibiotic has failed to hit key targets assessing its effect on survival in patients with Gram-negative pneumonia. The Phase …

Continue Reading →
biopharmaceutical

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop …

Continue Reading →
aTTP

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase III HERCULES study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura to be presented at he 59th Annual Meeting of the American Society of Hematology

Ablynx NV [Euronext Brussels and Nasdaq: ABLX] has announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six …

Continue Reading →